What policy defines recommended action for safe and effective use of medicines in pediatric populations and rare diseases?

• A. Orphan Drug Act (incentives) and pediatric regulations PREA/BPCA
• B. FDA Modernization Act
• C. Hatch-Waxman Act
• D. Food, Drug, and Cosmetic Act

Answer: (A)

Policies that create incentives and requirements to study medicines in children and for rare diseases shape how we ensure safe and effective use. The Orphan Drug Act provides incentives to develop drugs for rare diseases, making it financially feasible to pursue these often neglected areas. Pediatric considerations are then built into the regulatory process through pediatric regulations, namely PREA and BPCA. PREA requires sponsors of new drugs to address pediatric populations by submitting a Pediatric Study Plan and conducting studies to establish safety and efficacy in children, unless waived or deferred. BPCA complements this by offering incentives, including pediatric exclusivity, to encourage sponsors to complete pediatric studies even when not strictly required. Together, these policies define the recommended actions for bringing safe and effective medicines to children and to patients with rare diseases, by ensuring pediatric data is generated and properly labeled, while also stimulating development in these sectors. Other acts mentioned address broader regulatory aims or different priorities (like general drug safety under the FD&C Act or generic drug development under Hatch-Waxman) and do not focus specifically on pediatric and rare-disease drug development in the same way.